1-HEXACOSANOL
| Code | Size | Price |
|---|
| TAR-TN6751-50mg | 50mg | £94.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
Hexacosanol activates AMPK and hepatic autophagy and inhibits SREBP2, resulting in hypocholesterolemic activities and improvement of hepatic steatosis.
CAS:
506-52-5
Formula:
C26H54O
Molecular Weight:
382.717
Pathway:
PI3K/Akt/mTOR signaling; Membrane transporter/Ion channel; Chromatin/Epigenetic
Purity:
0.98
SMILES:
CCCCCCCCCCCCCCCCCCCCCCCCCCO
Target:
NPC1L1; AMPK
References
Lee JH, Jia Y, Thach TT, Han Y, Kim B, Wu C, Kim Y, Seo WD, Lee SJ. Hexacosanol reduces plasma and hepatic cholesterol by activation of AMP-activated protein kinase and suppression of sterol regulatory element-binding protein-2 in HepG2 and C57BL/6J mice. Nutr Res. 2017 Jul;43:89-99.
Saito M, Kinoshita Y, Satoh I, Shinbori C, Kono T, Hanada T, Uemasu J, Suzuki H, Yamada M, Satoh K. N-hexacosanol ameliorates streptozotocin-induced diabetic rat nephropathy. Eur J Pharmacol. 2006 Aug 21;544(1-3):132-7.